Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non Operating Income (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Non Operating Income for 10 consecutive years, with -$934000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 79.88% to -$934000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 120.0% increase, with the full-year FY2025 number at $1.0 million, up 120.0% from a year prior.
  • Non Operating Income was -$934000.0 for Q4 2025 at Ultragenyx Pharmaceutical, up from -$1.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $3.1 million in Q3 2024 to a low of -$4.6 million in Q4 2024.
  • A 5-year average of -$412650.0 and a median of -$557000.0 in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: crashed 1288.06% in 2022, then skyrocketed 666.67% in 2023.
  • Ultragenyx Pharmaceutical's Non Operating Income stood at -$410000.0 in 2021, then skyrocketed by 143.9% to $180000.0 in 2022, then surged by 666.67% to $1.4 million in 2023, then crashed by 436.45% to -$4.6 million in 2024, then skyrocketed by 79.88% to -$934000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Non Operating Income are -$934000.0 (Q4 2025), -$1.0 million (Q3 2025), and $2.1 million (Q2 2025).